A phase I/II clinical trial of oral vorinostat (MK0683) in combination with erlotinib in patients with relapsed/refractory non-small-cell lung cancer

Trial Profile

A phase I/II clinical trial of oral vorinostat (MK0683) in combination with erlotinib in patients with relapsed/refractory non-small-cell lung cancer

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 30 May 2014

At a glance

  • Drugs Erlotinib; Vorinostat
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Merck & Co
  • Most Recent Events

    • 09 Mar 2009 Actual patient number (23) added as reported by ClinicalTrials.gov.
    • 09 Mar 2009 Planned end date added to 1 Dec 2007 as reported by ClinicalTrials.gov.
    • 26 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top